UCSF Helen Diller Family Comprehensive Cancer Center
UCSF is the birthplace of oncogene biology (Bishop, Varmus) and KRAS G12C drugging (Shokat), and a leader in I-SPY adaptive breast trials.
Overview
The UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco is the birthplace of oncogene biology, where Bishop and Varmus made their Nobel-winning discovery, and of KRAS G12C drugging through Shokat's switch-II pocket; it holds NCI comprehensive designation and ranks thirty-third in the Newsweek/Statista oncology list. It leads the I-SPY 2 adaptive platform trial in breast cancer under Laura J. Esserman, runs the UCSF500 panel, and pioneered PSMA PET with Thomas A. Hope, alongside neuro-oncology and prostate programmes. Nuclide links it to KRAS and PSMA, to gallium-68 PSMA-11, to the Ostrem and Shokat paper, and to the MYC and telomere pathways. Whether MYC can be drugged directly, and tolerated, is the open question it is linked to. Alan Ashworth, Eric J. Small and Alan P. Venook are among the people listed.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to University of California, San Francisco, including child institutions. 2,864 works · 47,629 citations · 69% open access · 11% clinical trials · 2% reviews.
- Hope S. Rugo111 works
- Alan Paul Venook86 works
- Christine A. Miaskowski84 works
- Scarlett Lin Gomez73 works
- Aaron C. Logan68 works
- Ajay V. Maker58 works
- Hideho Okada58 works
- Yvette P. Conley57 works
- Iona C. Cheng55 works
- Lawrence H. Fong55 works
- I-SPY 2 platform trial
- KRAS chemistry
- PSMA PET
- Neuro-oncology
Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.
Similar pages
not linked directly; found by shared links- InstitutionUCLA Jonsson Comprehensive Cancer Center
Shares National Cancer Institute (NIH), Gallium-68 gozetotide (PSMA-11), PSMA, PSMA PET.
- IdeaBispecific PSMA/GRPR radioligands for discordant prostate cancer lesions
Shares PSMA, PSMA PET, Gallium-68.
- PersonMatthias Eiber
Shares Gallium-68 gozetotide (PSMA-11), PSMA PET, Gallium-68.
- AgentLocametz (kit for Ga-68 gozetotide)
Shares Gallium-68 gozetotide (PSMA-11), PSMA, PSMA PET, Gallium-68.
- TrialPSMA PET Combined With MRI for the Detection of PCa
- TermPSMA-RADS (PSMA reporting and data system)
Shares Gallium-68 gozetotide (PSMA-11), PSMA, PSMA PET.
- PersonStefano Fanti
Shares Gallium-68 gozetotide (PSMA-11), PSMA PET.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Gallium-68.